Efficacy of Neoveil covering ESD by novel Device Delivery Station System (DDSS) compared to Conventional Neoveil-ESD(CN-ESD) in Neoveil placement time: a randomized prospective study
Not Applicable
- Conditions
- Early differentiated gastric cancer over 20 mm in diameter
- Registration Number
- JPRN-UMIN000026377
- Lead Sponsor
- Ehime Rosai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria of definite advanced gastric cancer.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference of covering time between CN-ESD group and DDSS-ESD group
- Secondary Outcome Measures
Name Time Method 1.Post ESD bleeding 2.Post ESD perforation 3.Post ESD Deformity and stasis
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does the Device Delivery Station System (DDSS) utilize to improve Neoveil placement in early differentiated gastric cancer?
How does the efficacy of DDSS compare to conventional methods in treating early differentiated gastric cancer over 20 mm in diameter?
Are there specific biomarkers that correlate with successful Neoveil placement time in early differentiated gastric cancer patients?
What are the potential adverse events associated with Neoveil covering ESD using the Device Delivery Station System (DDSS)?
What are the related compounds or competitor drugs for Neoveil in the treatment of early differentiated gastric cancer?